MRK ▲ +0.2% - Merck & Co., Inc. $MRK - U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Merck shares rose 0.2% after the FDA approved a label update for WINREVAIR based on positive Phase 3 HYPERION trial data in newly diagnosed pulmonary arterial hypertension patients. The expanded labeling strengthens the drug's market position by demonstrating efficacy in an earlier disease stage, potentially broadening its addressable patient population. 22-SEP-2026 06:52 AM ET